PRETELL: PREvention of TELomere-related Complications After Lung Transplant

Summary

To evaluate the safety and efficacy of Danzol in lung transplant recipients with short telomeres. Subjects with short telomeres recipient of lung transplant, will be randomized in the first month post-transplant to either placebo or Danazol (200mg bid) in a 2:1 ratio.

Timeline

Start

2021-01-01

Primary completion

2021-11-20

Completion

2022-01-01

Outcome

Outcome not reported

Stopped (Business): “Lack of financial support”

Drugs

Indications